Mass production of highly active NK cells for cancer immunotherapy in a GMP conform perfusion bioreactor

Katharina Bröker, Evgeny Sinelnikov, Dirk Gustavus, Udo Schumacher, Ralf Pörtner, Hans Hoffmeister, Stefan Lüth & Werner Dammermann
NK cells have emerged as promising candidates for cancer immunotherapy, especially due to their ability to fight circulating tumor cells thereby preventing metastases formation. Hence several studies have been performed to generate and expand highly cytotoxic NK cells ex vivo, e.g., by using specific cytokines to upregulate both their proliferation and surface expression of distinct activating receptors. Apart from an enhanced activity, application of NK cells as immunotherapeutic agent further requires sufficient cell numbers and...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.